Quarterly ResultJul 23, 2026, 07:16 AM
West Pharma Q2 Net Sales $872.3M, Adj. EPS $2.37; Raises FY26 Guidance
AI Summary
West Pharmaceutical Services reported strong second-quarter 2026 financial results, with net sales increasing 13.8% to $872.3 million and adjusted-diluted EPS growing 28.8% to $2.37. The company exceeded expectations, driven by its High Value Product Components business, and consequently raised its full-year 2026 net sales and adjusted-diluted EPS guidance. Additionally, West repurchased 1.8 million shares for $454.3 million during the first half of 2026 and declared a third-quarter dividend of $0.22 per share.
Key Highlights
- Q2 2026 net sales increased 13.8% to $872.3 million; organic growth was 12.7%.
- Q2 2026 adjusted-diluted EPS rose 28.8% to $2.37.
- Operating cash flow for the first six months of 2026 was $213.9 million.
- The company repurchased 1.8 million shares for $454.3 million in H1 2026.
- Full-year 2026 net sales guidance raised to $3.345 billion - $3.380 billion.
- Full-year 2026 adjusted-diluted EPS guidance increased to $8.85 - $9.05.
- Proprietary Products segment net sales grew 16.6% to $722.6 million, with 15.5% organic growth.
- West Vantage segment net sales increased 2.0% to $149.7 million, with 0.8% organic growth.
Price Impact
More from WST